Logo
S

Synaffix BV

33 employees

Synaffix BV creates an antibody conjugation technology platform to aid in the treatment of cancer and other disorders.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Therapeutics
Cell Engagers
Bispecific Antibodies
Targeted Gene Therapy
Health Care
Antibody-Drug Conjugates (ADCs)

Date founded

2014

Funding rounds raised

S

Synaffix BV raised undisclosed on February 18, 2014

Investors: BOM (Brabantse Ontwikkelings Maatschappij), Aravis, BGV (BioGeneration Ventures) and M Ventures

FAQ